Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Cash & Equivalents (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Cash & Equivalents for 5 consecutive years, with $18.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 50.53% year-over-year to $18.3 million, compared with a TTM value of $18.3 million through Dec 2025, down 50.53%, and an annual FY2025 reading of $18.3 million, down 50.53% over the prior year.
  • Cash & Equivalents was $18.3 million for Q4 2025 at Aligos Therapeutics, down from $99.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $239.7 million in Q3 2021 and bottomed at $18.3 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $106.4 million, with a median of $92.7 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents tumbled 72.74% in 2024, then skyrocketed 180.49% in 2025.
  • Year by year, Cash & Equivalents stood at $186.8 million in 2021, then tumbled by 56.46% to $81.3 million in 2022, then soared by 66.82% to $135.7 million in 2023, then crashed by 72.74% to $37.0 million in 2024, then crashed by 50.53% to $18.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for ALGS at $18.3 million in Q4 2025, $99.1 million in Q3 2025, and $122.9 million in Q2 2025.